

CITATION REPORT

List of articles citing

Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

DOI: [10.1007/s40273-017-0488-2](https://doi.org/10.1007/s40273-017-0488-2)

Pharmacoeconomics, 2017, 35, 805-815.

Source: <https://exaly.com/paper-pdf/66038579/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?. <i>Dermatologic Therapy</i> , 2018 , 31, e12742	2.2	10
7	Early health economic modelling for a treatment candidate in hidradenitis suppurativa. <i>Journal of Medical Economics</i> , 2020 , 23, 1516-1524	2.4	2
6	Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. <i>Dermatologic Therapy</i> , 2021 , 34, e14643	2.2	3
5	The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. <i>Quality of Life Research</i> , 2021 , 30, 1477-1490	3.7	6
4	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-10	2.2	3
3	Quality of Life in Patients with Skin Disease and Their Cohabitants.		
2	Prevalence of low vitamin D levels in patients with Hidradenitis suppurativa in Jordan: A comparative cross-sectional study.. <i>PLoS ONE</i> , 2022 , 17, e0265672	3.7	0
1	Hidradenitis suppurativa. e068383		0